Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced today that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has appointed Eran Kuratz as head of supply chain and business process administration. The move comes as the company scales its contract development and manufacturing organization (CDMO) platform, a key driver of its growth strategy.
Kuratz brings more than 30 years of leadership experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is expected to streamline operations and support the company's expanded manufacturing footprint.
The appointment follows Scinai's acquisition of Recipharm Israel in the first quarter of 2026, which added a second development and manufacturing site in Yavne. Combined with its existing Jerusalem operations, the company now offers a broad range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing.
This expansion positions Scinai to meet growing demand for contract manufacturing services in the biopharmaceutical industry, particularly for companies seeking integrated development and production under one roof. The CDMO market has seen increasing consolidation and specialization, and Scinai's enhanced capabilities could make it a more competitive partner for biotech and pharma firms.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also operates its CDMO subsidiary, which serves external clients through facilities in both Jerusalem and Yavne, Israel.
The addition of Kuratz is part of Scinai's broader effort to strengthen its operational backbone as it scales. Effective supply chain management is critical in pharmaceutical manufacturing, where delays or disruptions can have significant regulatory and financial consequences. By appointing a veteran operations leader, Scinai aims to ensure reliability and efficiency across its expanded network.
Investors and industry observers will likely watch how these changes translate into contract wins and revenue growth. The CDMO segment is a notable revenue stream for Scinai, complementing its drug development pipeline. With two sites now operating, the company is better equipped to handle larger and more complex projects, potentially improving its competitive position.
For more information on the appointment and the company's CDMO services, visit the press release at https://ibn.fm/d9ktl. The latest news on Scinai Immunotherapeutics is available in the company's newsroom at https://ibn.fm/SCNI.
